Incyte Corporation (INCY)

NMS – Цена в реальном времени. Валюта: USD

99.13

-1.19 (-1.19%)

При закрытии: May 12, 2026, 4:00 PM EDT

99.13

0.00 (0.00%)

После закрытия: May 12, 2026, 5:39 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Incyte Corporation (INCY)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Incyte Corporation (INCY)

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why Incyte (INCY) is a Top Value Stock for the Long-Term

Here's Why Incyte (INCY) is a Strong Growth Stock

Why Incyte (INCY) is a Top Momentum Stock for the Long-Term

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Видео

Пресс-релизы

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Search stocks

Incyte Corporation (INCY)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Incyte Corporation (INCY)

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why Incyte (INCY) is a Top Value Stock for the Long-Term

Here's Why Incyte (INCY) is a Strong Growth Stock

Why Incyte (INCY) is a Top Momentum Stock for the Long-Term

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Видео

Пресс-релизы

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease